Cure My Disease

Don't miss your cure!

 Log in / Sign up

Higher dose of common drug may raise hospital risk for seniors with kidney trouble

NCT ID NCT07382960

Completed Knowledge-focused Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at 1,100 older adults (65+) with advanced chronic kidney disease who started taking pramipexole, a drug for restless legs or Parkinson's. Researchers compared a very low starting dose (0.125 mg/day) to slightly higher doses (0.25 or 0.375 mg/day) to see if the higher doses increased the risk of hospitalization, emergency visits, or death within 30 days. The goal is to find safer prescribing practices for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pramipexole
What this could lead to
If successful, this study could help doctors choose safer starting doses of pramipexole for older adults with kidney disease, reducing hospital visits.
What could go wrong
This is an observational study, not a controlled trial, so it can only show links, not cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE (CKD) OLDER ADULTS (65 YEARS AND OLDER)

Contacts and locations

Locations

  • London Health Sciences Centre Research Institute

    London, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.